5.43
Schlusskurs vom Vortag:
$5.71
Offen:
$5.62
24-Stunden-Volumen:
564.82K
Relative Volume:
2.45
Marktkapitalisierung:
$272.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-76.41M
KGV:
-2.8281
EPS:
-1.92
Netto-Cashflow:
$-64.56M
1W Leistung:
-14.35%
1M Leistung:
-27.60%
6M Leistung:
-37.73%
1J Leistung:
-24.27%
Aura Biosciences Inc Stock (AURA) Company Profile
Firmenname
Aura Biosciences Inc
Sektor
Branche
Telefon
(617)500-8864
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie AURA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AURA
Aura Biosciences Inc
|
5.43 | 272.72M | 0 | -76.41M | -64.56M | -1.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-25 | Eingeleitet | H.C. Wainwright | Buy |
2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
2023-04-17 | Fortgesetzt | BTIG Research | Buy |
2022-07-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
Aura Biosciences expands board with oncology leader By Investing.com - Investing.com South Africa
Aura Biosciences Announces Appointment Of Teresa Bitetti To Board Of Directors - MarketScreener
Aura Biosciences expands board with oncology leader - Investing.com India
Aura Biosciences Expands Board with New Director Appointment - TipRanks
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - GlobeNewswire
Major Leadership Move: Takeda's Oncology Chief Strengthens Aura Biosciences' Commercial Strategy - Stock Titan
Aura Biosciences stock hits 52-week low at $5.75 amid market challenges By Investing.com - Investing.com South Africa
Aura Biosciences stock hits 52-week low at $5.75 amid market challenges - Investing.com
Are Investors Keen On Selling Holdings In Aura Biosciences Inc (NASDAQ: AURA)? - stocksregister.com
(AURA) Long Term Investment Analysis - news.stocktradersdaily.com
Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World
Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St
Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks
What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World
Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - markets.businessinsider.com
Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks
Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology
Bel-sar shows promising safety, efficacy in NMIBC - Urology Times
Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK
Aura Biosciences Reports Progress in Cancer Trials - TipRanks
Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK
Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences Reports Positive Phase 1 Trial Results in Non-Muscle Invasive Bladder Cancer and Advances Clinical Pipeline - Nasdaq
Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - Stock Titan
Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks
Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa
Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia
Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks
Aura Biosciences stock hits 52-week low at $6.58 amid market shifts By Investing.com - Investing.com South Africa
Buy Rating for Aura Biosciences Inc. Driven by Promising Phase 1 Trial Results and Future Revenue Potential - TipRanks
Aura Biosciences Reports 'Robust' Anti-Tumor Immune Response From Phase 1 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer - MarketScreener
Aura reports promising bladder cancer trial results - Investing.com India
Aura Biosciences announces data from Phase 1 trial of bel-sar in NMIBC - TipRanks
Positive Data from Phase 1 Trial of Bel-sar in Patients - GlobeNewswire
Breakthrough: New Bladder Cancer Drug Achieves 80% Response Rate in Clinical Trial - Stock Titan
With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest - Yahoo Finance
Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest - Defense World
Analysts Set Groupon, Inc. (NASDAQ:GRPN) PT at $17.33 - Defense World
Innovative Industrial Properties, Inc. (NYSE:IIPR) Receives $102.00 Average Target Price from Analysts - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Target Price from Brokerages - Defense World
Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com
Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday - Defense World
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire
Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World
H.C. Wainwright maintains $22 target on Aura Biosciences stock By Investing.com - Investing.com UK
Buy Rating for Aura Biosciences Driven by Promising Bel-sar Developments and Market Potential - TipRanks
Promising Developments in Aura Biosciences Inc’s Clinical Trials Lead to Buy Rating - TipRanks
Finanzdaten der Aura Biosciences Inc-Aktie (AURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):